Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.

Anti-cancer drugs - 1 Mar 2026

Pilco-Janeta Daniel F, De la Cruz-Puebla Myriam

Abstract excerpt

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are among the most common oncogenic drivers in human cancer and are associated with poor prognosis, limited therapeutic options, and frequent resistance to standard treatments. The approval of the first direct KRAS G12C inhibitors demonstrated that mutant KRAS can be targeted clinically, but their efficacy is restricted to a narrow allelic subset and is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to KEAP1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SOS1 gene

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 41437507
DOI: 10.1097/CAD.0000000000001801

Genes

KRAS
KEAP1
SOS1
STK11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.PMID 41437507Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.Semantic proximity Read ↗

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.Semantic proximity Read ↗

Recent advances in therapeutic targeting of the KRAS pathway in cancer.Semantic proximity Read ↗

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.Semantic proximity Read ↗

Therapeutics Targeting Mutant KRAS.Semantic proximity Read ↗

KRAS mutation: from undruggable to druggable in cancerSemantic proximity Read ↗

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.Semantic proximity Read ↗

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.